GE HealthCare Technologies and its subsidiaries are currently working on the development of 85 products that fall under the Diagnostic Imaging, Digital Health and In Vitro Diagnostics markets. GlobalData’s report GE HealthCare Technologies Medical Device Development provides an overview of the company’s pipeline landscape and offers detailed analysis of its products in development. Buy the report here.
Smarter leaders trust GlobalData
The company’s devices in development are either in the late stage of development or are in an early development stage.
The main research and development focus of GE HealthCare Technologies is on cancer, followed by cardiovascular diseases, nervous system diseases, respiratory tract diseases, infectious diseases, nutritional and metabolic diseases, immune system diseases, orthopedic diseases, women's health and digestive system diseases.
GE HealthCare Technologies: Top therapeutic area(s) by pipeline products
For a complete picture of the developmental pipeline for GE HealthCare Technologies medical devices, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
The medical devices pipeline data used in this article were obtained from the Medical Pipeline Products Database of GlobalData’s Medical Intelligence Center. Pipeline Products database is a comprehensive source of information on medical devices, it covers 39K products which are in development stage and intended for diagnosis, treatment, and management of diseases/conditions/symptoms directly or indirectly. The pipeline products included in the database are sourced from reliable and authenticated sources, such as company websites, SEC filings, conference presentations, analyst presentations, news releases, clinical trial registries, and grants. The information is collected by following systematic research techniques and proprietary methodology.
